AXIM BIOTECHNOLOGIES, INC.

AXIM Biotechnologies has generated zero cyber incidents and zero red-flag 8-K filings across our 90-day monitoring window, suggesting baseline operational stability in the recent period. However, a compressed timeframe and absence of acute events do not constitute a complete risk picture—particularly for a biotech entity where dilution, capital structure changes, and financing patterns typically drive shareholder impact. The full $49 Report extends analysis to 12 months of SEC filings, calculates dilution risk scores, contextualizes all 8-K activity, maps financing history, and surfaces AI-detected risk signals missed by standard screening. The full $49 Report adds dilution trajectory, 12-month 8-K context, and capital adequacy assessment.